RT Journal Article SR Electronic T1 SHP2 Inhibition May Resensitize NSCLC Tumors to ALK Inhibitors JF Cancer Discovery JO Cancer Discov FD American Association for Cancer Research SP OF10 OP OF10 DO 10.1158/2159-8290.CD-RW2018-043 VO 8 IS 5 YR 2018 UL http://cancerdiscovery.aacrjournals.org/content/8/5/OF10.abstract AB Targeting SHP2 suppresses ALK inhibitor resistance caused by tyrosine kinase reactivation.